09.25.25 -- Engineering Off-The-Shelf Cell Therapies For Cancer & Autoimmune Disease

The shift from "scale-up" to "scale-out" in genetic medicine enhances production speed, revolutionizing pharmaceutical manufacturing and accelerating life-saving therapies for global patient populations.

Discover how high-throughput, single-cell technologies combined with machine learning and automation are transforming clone selection to accelerate timelines and improve accuracy in bioprocessing.

Evaluate tangential flow filtration (TFF) formats and membrane chemistries for AAV gene therapy processing, assessing performance, scalability, economy, and closed processing options.

Release by exception reduces the manpower needed for reviewing QC batch information, only requiring quality teams to review information when predefined targets are not met and lowering costs.

This paper underscores the 4D-Nucleofector® LV Unit as a pivotal tool for translating genetic modification technologies into scalable, safe, and effective therapeutic solutions.

We outline the incorporation of magnetic bead separation technology into a cell processing platform designed specifically for cell therapy applications.

Here we explore the use of viral vectors in gene therapies, as well as factors that negatively affect them during manufacturing.

Scaling up life-saving gene-edited cell therapies means tackling production inefficiencies. Overcoming the time-consuming and risky cell washing step is crucial for clinical and commercial success.

Advancements in recombinant protein production have improved efficiency and quality. However, optimizing cell culture media remains crucial to ensuring maximized yield and desirable product attributes.

Tube welding and biosafety cabinets present significant costs and risks for small-volume aseptic processing. Modern single-use aseptic connectors offer a more efficient alternative.

Patent expiry of original product enables 3P innovation to design enhanced equivalent DPI filling system for developers and CMOs.